Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP604772.RAfcMgvLIssJfBEy0QFiSSKXAvIKk_bMd9PE5asQKF6FQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP604772.RAfcMgvLIssJfBEy0QFiSSKXAvIKk_bMd9PE5asQKF6FQ130_assertion type Assertion NP604772.RAfcMgvLIssJfBEy0QFiSSKXAvIKk_bMd9PE5asQKF6FQ130_head.
- NP604772.RAfcMgvLIssJfBEy0QFiSSKXAvIKk_bMd9PE5asQKF6FQ130_assertion description "[These findings provide a rationale for use of LRH-1 as immunotherapeutic target antigen to treat residual or persisting myeloid malignancies after allogeneic SCT.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP604772.RAfcMgvLIssJfBEy0QFiSSKXAvIKk_bMd9PE5asQKF6FQ130_provenance.
- NP604772.RAfcMgvLIssJfBEy0QFiSSKXAvIKk_bMd9PE5asQKF6FQ130_assertion evidence source_evidence_literature NP604772.RAfcMgvLIssJfBEy0QFiSSKXAvIKk_bMd9PE5asQKF6FQ130_provenance.
- NP604772.RAfcMgvLIssJfBEy0QFiSSKXAvIKk_bMd9PE5asQKF6FQ130_assertion SIO_000772 19074734 NP604772.RAfcMgvLIssJfBEy0QFiSSKXAvIKk_bMd9PE5asQKF6FQ130_provenance.
- NP604772.RAfcMgvLIssJfBEy0QFiSSKXAvIKk_bMd9PE5asQKF6FQ130_assertion wasDerivedFrom befree-20150227 NP604772.RAfcMgvLIssJfBEy0QFiSSKXAvIKk_bMd9PE5asQKF6FQ130_provenance.
- NP604772.RAfcMgvLIssJfBEy0QFiSSKXAvIKk_bMd9PE5asQKF6FQ130_assertion wasGeneratedBy ECO_0000203 NP604772.RAfcMgvLIssJfBEy0QFiSSKXAvIKk_bMd9PE5asQKF6FQ130_provenance.